Treating comorbid substance use disorders in schizophrenia

International Review of Psychiatry

Volumn 22, Issue 2, 2010, Pages 191-201

  Lubman, Dan I ^a   King, Joel A ^a,b   Castle, David J ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Alcohol; Cannabis; Cocaine; Heroin; Pharmacotherapy; Psychological; Schizophrenia; Treatment

Indexed keywords

CLOZAPINE; DISULFIRAM; HALOPERIDOL; NALTREXONE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

AGRANULOCYTOSIS; ALCOHOLISM; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; DISEASE ASSOCIATION; EPIDEMIOLOGICAL DATA; EVIDENCE BASED PRACTICE; GROUP THERAPY; HUMAN; LONG TERM CARE; MOTIVATION; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEIZURE; SOCIAL PSYCHOLOGY; SUBSTANCE ABUSE; WITHDRAWAL SYNDROME;

COMBINED MODALITY THERAPY; COMMUNITY MENTAL HEALTH SERVICES; COMORBIDITY; DRUG THERAPY; HUMANS; PREVALENCE; PSYCHOTHERAPY; PSYCHOTHERAPY, GROUP; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS;

EID: 77952817990     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.3109/09540261003689958     Document Type: Review

References (74)

1. Abram, K. M., & Teplin, L. A. (1991). Co-occurring disorders among mentally ill jail detainees. Implications for public policy. American Psychologist, 46, 1036-1045.
2. Akerele, E., & Levin, F. R. (2007). Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia. American Journal on Addictions, 16, 260-268.
3. Albanese, M. J., Khantzian, E. J., Murphy, S. L., & Green, A. I. (1994). Decreased substance use in chronically psychotic patients treated with clozapine. American Journal of Psychiatry, 151, 780-781.
4. Baker, A., Lewin, T., Reichler, H., Clancy, R., Carr, V., Garrett, R. et al. (2002). Evaluation of a motivational interview for substance use within psychiatry in-patient services. Addiction, 97, 1329-1337.
5. Baker, A., Hides, L., & Lubman, D. I. (2010). Treatment of cannabis use among people with psychotic and depressive disorders: A systematic review. Journal of Clinical Psychiatry, 71, 247-254.
6. Baker, A. L., Lubman, D. I., & Hides, L. (2010). Smoking and schizophrenia: Treatment approaches within primary care. Primary Psychiatry, 17, 49-54.
7. Barrowclough, C., Haddock, G., Tarrier, N., Lewis, S. W., Moring, J., & O'Brien, R. (2001). Randomised controlled trial of cognitive behavioural therapy plus motivational intervention for schizophrenia and substance use. American Journal of Psychiatry, 158, 1706-1713.
8. Barrowclough, C., Haddock, G., Fitzsimmons, M., & Johnson, R. (2006). Treatment development for psychosis and co-occurring substance misuse: A descriptive review. Journal of Mental Health, 15, 619-632.
9. Bellack, A. S., Bennett, M. E., Gearon, J. S., Brown, C. H., & Yang, Y. (2006). A randomised clinical trial of a new behavioural treatment for drug abuse in people with severe and persistent mental illness. Archives of General Psychiatry, 63, 426-432.
10. Beresford, T. P., Clapp, L., Martin, B., Wiberg, J. L., Alfers, J., & Beresford, H. F. (2005). Aripiprazole in schizophrenia with cocaine dependence: A pilot study. Journal of Clinical Psychopharmacology, 25, 363-366.
11. Brunette, M. F., Drake, R. E., Woods, M., & Hartnett, T. (2001). A comparison of long-term and short-term residential treatment programs for dual diagnosis patients. Psychiatric Services, 52(4), 526-528.
12. Buckley, P. F. (2006). Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness. Journal of Clinical psychiatry, 67(S7), 5-9.
13. Casas, M., Gutierrez, M., Gilbert, J., Bobes, J., Roncero, C., & Ocatvio, I. (2001). [Risperidone in the treatment of psychotic patients with opiate abuse and dependence]. Actas Espanolas de Psiquiatria, 29, 380-385.
14. Castle, D., & Ho, V. (2003). Substance use and psychosis: What can be done? Psychiatry, Psychology and Law, 10, 149-153.
15. Chambers, R. A., Krystal, J. H., & Self, D. W. (2001). A neurobiological basis for substance abuse comorbidity in schizophrenia. Biological Psychiatry, 50, 71-83.
16. Cleary, M., Hunt, G. E., Matheson, S., Siegfried, N., & Walter, G. (2008). Psychosocial treatment programs for people with both severe mental illness and substance misuse. Schizophrenia Bulletin, 34(2), 226-228. (Pubitemid 351323344)
17. de Leon, J., & Diaz, F. J. (2005). A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophrenia Research, 76, 135-157.
18. Dixon, L. B., Dickerson, F., Bellack, A. S., Bennett, M., Dickinson, D., Goldberg, R. W. et al. (2010). The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophrenia Bulletin, 36(1), 48-70.
19. Drake, R. E., McHugo, G. J., Gregory, J., Clark, R. E., Teague, G. B., Xie, H. et al. (1998). Assertive community treatment for patients with co-occurring severe mental illness and substance use disorders: A clinical trial. American Journal of Orthopsychiatry, 68, 201-215.
20. Drake, R. E., Mercer-McFadden, C., Mueser, C., Kim, T., McHugo, G. J., & Bond, G. R. (1998). Review of integrated mental health and substance abuse treatment for patients with dual disorders. Schizophrenia Bulletin, 24, 589-608.
21. Drake, R. E., O'Neal, E. L., & Wallach, M. A. (2008). A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. Journal of Substance Abuse Treatment, 34, 123-138.
22. Drake, R. E., Wallach, M. A., Teague, G. B., Freeman, D. H., Paskus, T. S., & Clark, T. A. (1991). Housing instability and homelessness among rural schizophrenic patients. American Journal of Psychiatry, 148, 330-336.
23. Drake, R. E., Xie, H., McHugo, G. J., & Green, A. I. (2000). The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophrenia Bulletin, 26, 441-449.
24. Drake, R. E., Essock, S. M., Shaner, A., Carey, K. B., Minkoff, K., Kola, L. et al. (2001). Implenting dual diagnosis services for clients with severe mental illness. Psychiatric Services, 52(4), 469-476.
25. Drake, R. E., Mueser, K. T., Brunette, M. F., & McHugo, G. J. (2004). A review of treatments for people with severe mental illnesses and co-occurring substance use disorders. Psychiatric Rehabilitation Journal, 27, 360-374.
26. Essock, S. M., Mueser, K. T., Drake, R. E., Covell, N. H., McHugo, G. J., Frisman, L. K. et al. (2006). Comparison of ACT and standard case management for delivering integrated treatment for co-occurring disorders. Psychiatric Services, 57, 185-196.
27. Green, A. I., Drake, R. E., Brunette, M. F., & Noordsy, D. L. (2007). Schizophrenia and co-occurring substance use disorder. American Journal of Psychiatry, 164, 402-408.
28. Green, A. I., Noordsy, D. L., Brunette, M. F., & O'Keefe, C. (2008). Substance abuse and schizophrenia: Pharmacotherapeutic intervention. Journal of Substance Abuse Treatment, 34, 61-71.
29. Green, A. I., Zimmet, S. V., Straus, R. D., & Schildkraut, J. J. (1999). Clozapine for comorbid substance use disorder and schizophrenia: Do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harvard Review of Psychiatry, 6, 287-296.
30. Green, B., Kavanagh, D. J., & Young, R. M. (2004). Reasons for cannabis use in men with and without psychosis. Drug and Alcohol Review, 23, 445-453.
31. Haddock, G., Barrowcough, C., Tarrier, N., Moring, J., O'Brien, R., Schofield, N. et al. (2003). Randomised controlled trial of cognitive- behavioural therapy and motivational interviewing for schizophrenia and substance use: 18 month, carer and economic outcomes. British Journal of Psychiatry, 183, 418-426.
32. Hellerstein, D. J., Rosenthal, R. N., & Miner, C. R. (1995). A prospective study of integrated outpatient treatment for substance abusing schizophrenic patients. American J Addict., 4, 33-42.
33. Hercus, M., Lubman, D. I., & Hellard, M. (2005). Blood-borne viral and sexually transmissible infections among psychiatric populations: What are we doing about them? Australian and New Zealand Journal of Psychiatry, 39, 849-855.
34. Hides, L., Cotton, S. M., Devlin, H., Cotton, S., Aitken, C., Gibbie, T. et al. (2009). The reliability and validity of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in first-episode psychosis. Addictive Behaviors, 34, 821-825.
35. Hides, L., Dawe, S., Kavanagh, D. J., & Young, R. M. (2006). Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study. British Journal of Psychiatry, 189, 137-143.
36. Hides, L., Lubman, D. I., & Dawe, S. (2004). Models of co-occurring substance misuse and psychosis: Are personality traits the missing link? Drug and Alcohol Review, 23, 425-432.
37. James, W., Preston, N., Koh, G., Spencer, C., Kisely, S. R., & Castle, D. J. (2004). A group intervention which assists patients with dual diagnosis reduce their drug use: A randomised controlled trial. Psychological Medicine, 34, 983-990.
38. Kavanagh, D. J., Young, R., White, A., Saunders, J., Shockley, N., Wallis, J. et al. (2003). Start over and survive: A brief intervention for substance abuse in early psychosis. In H. Graham, M. Birchwood, A. Copello & K. Mueser (Eds.), Substance misuse in psychosis: approaches to treatment and service delivery. The wiley series in clinical psychology (pp. 244-258). Chichester, England: John Wiley & Sons, Inc.
39. Kelly, D. L., Gale, E. A., & Conley, R. R. (2003). Clozapine treatment in patients with prior substance abuse. Canadian Journal of Psychiatry, 48, 111-114.
40. Khantzian, E. J. (1997). The self-medication hypothesis of substance use disorders: A reconsideration and recent applications. Harvard Review of Psychiatry, 4, 231-244.
41. Lambert, M., Conus, P., Lubman, D. I., Wade, D., Yuen, H., Moritz, S. et al. (2005). The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatrica Scandinavica, 112, 141-148.
42. Lambert, T. J., & Castle, D. J. (2003). Pharmacological approaches to the management of schizophrenia. Medical Journal of Australia, 178, S57-61.
43. Lehman, A. F., Herron, J. D., Schwartz, R. P., & Myers, C. P. (1993). Rehabilitation for adults with severe mental illness and substance use disorders: A clinical trial. Journal of Nervous and Mental Disease, 181, 86-90.
44. Ley, A., & Jeffrey, D. (2003). Cochrane review of treatment outcome studies and its implications for future development. In H. L. Graham, M. Birchwood, A. Copello & K. Mueser (Eds.), Substance misuse in psychosis: Approaches to treatment and service delivery. The wiley series in clinical psychology. Chichester, England: John Wiley & Sons, Inc.
45. Littrell, K. H., Petty, R. G., Hilligoss, N. M., Peabody, C. D., & Johnson, C. G. (2001). Olanzapine treatment for patients with schizophrenia and substance abuse. Journal of Substance Abuse Treatment, 21, 217-221.
46. Lubman, D. I., & Berk, M. (2010). Pharmacotherapy for co-occurring alcohol and drug disorders in schizophrenia and bipolar disorder: Where is the evidence? Acta Neuropsychiatrica, 22, 95-97.
47. Lubman, D. I., Hides, L., & Elkins, K. (2008). Dual diagnosis: An issue of dual disorders or a dual system? In D. Moore & P. Dietze (Eds.), Theory, evidence and context: Contemporary innovations in alcohol and other drug practice in Australia (pp. 127-138). Oxford: Oxford University Press.
48. Lubman, D. I., & Sundram, S. (2003). Substance misuse in patients with schizophrenia: A primary care guide. Medical Journal of Australia, 178, S71-75.
49. Lubman, D. I., Yucel, M., & Pantelis, C. (2004). Addiction, a condition of compulsive behaviour? Neuroimaging and neuropsychological evidence of inhibitory dysregulation. Addiction, 99, 1491-1502.
50. Mueser, K. T., Drake, R. E., & Wallach, M. A. (1998). Dual diagnosis: A review of etiological theories. Addictive Behaviors, 23, 717-734.
51. Olivier, D., Lubman, D. I., & Fraser, R. (2007). Tobacco smoking within psychiatry inpatient settings: Biopsychosocial perspective. Australian and New Zealand Journal of Psychiatry, 41, 572-580.
52. Owen, R. R., Fischer, E. P., Booth, B. M., & Cuffel, B. J. (1996). Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatric Services, 47, 853-858.
53. Petrakis, I. L., Nich, C., & Ralevski, E. (2006). Psychotic spectrum disorders and alcohol abuse: A review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophrenia Bulletin, 32, 644-654.
54. Petrakis, I. L., O'Malley, S., Rounsaville, B., Poling, J., McHugh-Strong, C., Krystal, J. H. et al. (2004). Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacol (Berl), 172, 291-297.
55. Potvin, S., Pampoulova, T., Mancini-Marië, A., Lipp, O., Bouchard, B.-H., & Stip, E. (2006). Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder. Journal of Neurology Neurosurgery and Psychiatry, 77, 796-798.
56. Potvin, S., Stip, E., & Jean-Yves, R. (2004). The effect of quetiapine on cannabis use in 8 psychosis patients with drug dependency. Canadian Journal of Psychiatry, 49, 711.
57. Prochaska, J. O., DiClemente, C. C., & Norcross, J. (1992). In search of how people change: Applications to addictive behaviors. American Psychologist, 47, 1102-1114.
58. Regier, D. A., Farmer, M. E., Rae, D. S., Locke, B. Z., Keith, S. J., Judd, L. L. et al. (1990). Comorbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiological Catchment Area (ECA) study. JAMA, 264, 2511-2518.
59. Rubio, G., Martinez, I., Ponce, G., Jiménez-Arriero, M. A., López-Muñoz, F., & Álamo, C. (2006). Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Canadian Jouranl of Psychiatry, 51, 531-539. (Pubitemid 44166341)
60. San, L., Arranz, B., & Martinez-Raga, J. (2007). Antipsychotic drug treatment of schizophrenic patients with substance abuse disorders. European Addiction Research, 13, 230-243.
61. Sayers, S. L., Campbell, E. C., Kondrich, J., Mann, S. C., Cornish, J., O'Brien, C. et al. (2005). Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. Journal of Nervous and Mental Disease, 193, 379-386.
62. Schilkrut, R., Cabrera, J. et al. (1988). Neuroleptics in the treatment of drug dependence in schizophrenics: A study with flupenthixol decanoate. Psychopharmacology, 96, 342.
63. Siris, S. G. (1990). Pharmacological treatment of substanceabusing schizophrenic patients. Schizophrenia Bulletin, 16, 111-122.
64. Smelson, D. A., Losonczy, M. F., & Davis, C. W. (2002). Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Canadian Journal of Psychiatry, 47, 671-675.
65. Smelson, D. A., Ziedonis, D., Williams, J., Losonczy, M. F., Williams, J., Steinberg, M. L. et al. (2006). The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: A preliminary report. Journal of Clinical Psychopharmacology, 26, 9-12.
66. Soyka, M., Aichmuller, C., V Bardeleben, U., Beneke, M., Glaser, T., Hornung Knobel, S. et al. (2003). Flupenthixol in relapse prevention in schizophrenics with comorbid alcoholism: Results from an open clinical study. European Addiction Research, 9, 65-72.
67. Spencer, C., Castle, D., & Michie, P. T. (2002). Motivations that maintain substance use among individuals with psychotic disorders. Schizophrenia Bulletin, 28(2), 233-247.
68. Swartz, M. S., Swanson, J. W., Hiday, V. A., Borum, R., Wagner, H. R., & Burns, B. J. (1998). Violence and severe mental illness: The effects of substance abuse and nonadherence to medication. American Journal of Psychiatry, 155, 226-231.
69. Tsuang, J. W., Eckman, T. E., Shaner, A., & Marder, S. R. (1999). Clozapine for substance-abusing schizophrenic patients. American Journal of Psychiatry, 156, 1119-1120.
70. Wade, D., Harrigan, S., Edwards, J., Burgess, P. M., Whelan, G., & McGorry, P. D. (2006). Substance misuse in first-episode psychosis: 15-month prospective follow-up study. British Journal of Psychiatry, 189, 229-234 (Pubitemid 44343467)
71. Wade, D., Hides, L., Baker, A., & Lubman, D. I. (2009). Substance misuse in first-episode psychosis. In H. J. Jackson & P. D. McGorry (Eds.), The recognition and management of early psychosis: A preventive approach (pp. 243-256). Cambridge: Cambridge University Press.
72. Yucel, M., & Lubman, D. I. (2007). Neurocognitive and neuroimaging evidence of behavioural dysregulation in human drug addiction: Implications for diagnosis, treatment and prevention. Drug and Alcohol Review, 26, 33-39.
73. Zammit, S., Moore, T. H., Barnes, T. R. E., Jones, P. B., & Burke, M. (2008). Effects of cannabis use on outcomes of psychotic disorders: Systematic review. British Journal of Psychiatry, 193, 357-363.
74. Zimmet, S. V., Strous, R. D., Burgess, E. S., Kohnstamm, S. A. B., & Green, A. I. (2000). Effect of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: A retrospective study. Journal of Clinical Psychopharmacology, 20, 94-98.